PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons

id="title" class="nomar"Atoms-to-Animals: The Immune Function Network

This biological project consists of investigators from the Albert Einstein College of Medicine, Harvard Medical School, and the University of Washington. It is partnered with the PSI High-Throughtput Structure Determination center NYSGRC

IFN Investigators

  • Albert Einstein College of Medicine
    S. Nathenson, PI
    S. Almo, Co-PI
    A. Fiser, Co-PI
    W. Edelmann, Co-PI
  • Harvard Medical School
    A. Sharpe, Co-PI
  • University of Washington
    D. Baker, Co-PI

Contact Information

Stanley Nathanson
stanley.nathenson@einstein.yu.edu

Steven C. Almo
steve.almo@einstein.yu.edu

Research Description

The Immune Function Network (IFN), a consortium of immunologists, geneticists, computational biochemists, and high throughput structural biologists, is committed to the coordinated structural, in vitro biochemical and in vivo functional analyses of the secreted molecules and ectodomains of cell surface molecules which control adaptive and innate immunity. These molecules are validated targets for immune-based therapies to treat a wide range of autoimmune diseases, infectious diseases and cancers, and are indeed therapeutics in their own right. The IFN, subscribes to a series of underlying principles: 1) target selection supports hypothesis-driven structural biology by identifying unique primary amino acid sequence signatures that predict unique structural features, which are in turn responsible for unique biological function; 2) the high resolution structures of these molecules are exceptionally revealing as they inform on oligomeric state, valency, specificity and general architectural features, all of which are fundamental mechanistic contributors to immune function; 3) these structures can be readily exploited by biochemical and computational approaches to guide the generation of molecules with specifically altered biochemical and biophysical properties; 4) these “surgically-defined” mutants represent novel reagents which will lead to new mechanistic insights in in vitro cell-based assays and in vivo animal models of disease; 5) the molecules predicted to be most informative will guide the generation of knock-in mouse models to provide in vivo structure-function relationships for innate and adaptive immunity. This “Atoms-to-Animals” approach represents the next step in the evolution of Structural Biology as it maximally leverages structural information and provides a comprehensive and powerful paradigm for the study of normal, pathological, and therapeutic immune responses.

The research activities of the IFN will be conducted in collaboration with the New York Structural Genomics Research Consortium.

Structures, Targets, Publications and Technologies

IFN Structures in RCSB PDB
IFN Targets in TargetTrack
IFN SBKB Publications Page

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health